Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 345 participants.

Also called NCT01475461

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 345 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01475461
  • EudraCT 2011-004002-25
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Hungary, India, Philippines, Romania, Slovakia, South Africa, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01475461. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2017-01-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Placebo
Intervention (Drug)
PF-04937319 - 3mg
Intervention (Drug)
PF-04937319 - 20mg
Intervention (Drug)
PF-04937319 - 50mg
Intervention (Drug)
PF-04937319 - 100mg
Intervention (Drug)
Sitagliptin - 100mg
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01475461
Content hash
9c8f7a6f9c198a429024c24658188ea49f54ca80db9ef70769e54a57744e43bb